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Objectives: Nitrofurantoin’s use has increased exponentially since recent guidelines repositioned it as first-line
therapy for uncomplicated lower urinary tract infection (UTI). We conducted a systematic review and meta-
analysis to assess nitrofurantoin’s efficacy and toxicity in the treatment of lower UTI.
Methods: We performed a systematic review of all human controlled clinical trials published from 1946 to 2014
and assessing short-term (≤14 days) nitrofurantoin for lower UTI. Meta-analyses assessing efficacy and adverse
events were conducted on randomized trials.
Results: Twenty-seven controlled trials including 4807 patients fulfilled entry criteria; most were conducted
between the 1970s and 1990s and were at increased risk for various biases. Nitrofurantoin appears to have
good clinical and microbiological efficacy for UTI caused by common uropathogens, with clinical cure rates vary-
ing between 79% and 92%. The most methodologically robust studies surveyed indicate overall equivalence
between nitrofurantoin when given for 5 or 7 days and trimethoprim/sulfamethoxazole, ciprofloxacin and amoxi-
cillin. Meta-analyses of randomized controlled trials confirmed equivalence in clinical cure, but indicated a slight
advantage to comparator drugs in microbiological efficacy (risk ratio 0.93, 95% CI 0.89–0.97). If given for only
3 days, nitrofurantoin’s clinical efficacy was diminished (61%–70%). Toxicity was infrequent (5%–16% in the 17
reporting studies), mild, reversible and predominantly gastrointestinal; meta-analyses confirmed no difference
between nitrofurantoin and comparators. Hypersensitivity reactions such as pulmonary fibrosis and hepatotox-
icity were not observed. Acquisition of resistance to nitrofurantoin is still relatively rare.
Conclusions: When given short term for lower UTI, nitrofurantoin has good clinical and microbiological efficacy;
toxicity is mild and predominantly gastrointestinal.
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Introduction
The nitration of heterocyclic compounds in the 1940s led to the
creation of thousands of nitrofurans,1 among which the best clin-
ically known is nitrofurantoin. Approved by the FDA in 1953 for
the treatment of lower urinary tract infection (UTI), nitrofurantoin
was prescribed widely for the next two decades, until its popular-
ity waned in the 1970s with the advent of trimethoprim/sulfa-
methoxazole and the b-lactam antibiotics. Recently, however,
increasing resistance to trimethoprim/sulfamethoxazole and
fluoroquinolones along with a near absence of novel oral antibio-
tics in the anti-infective arsenal have led to renewed interest in
this old drug. Beginning in the late 2000s—and coincident with
the rise in ESBL-producing and carbapenem-resistant bacteria—
several guidelines were revised to reposition nitrofurantoin as
first-line therapy for uncomplicated lower UTI.2 – 5 Since then, its
consumption has increased exponentially (Figure 1). Indeed,
large population-level datasets point to a significant reliance on
nitrofurantoin even in patient groups for whom this drug has his-
torically been discouraged, such as men and the elderly.6,7
Nitrofurantoin possesses several mechanisms of antimicrobial
action, none of which is fully understood. It is known that intracel-
lular nitroreductases produce the active form of the drug via
reduction of the nitro group; resultant intermediate metabolites
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are highly active, binding to bacterial ribosomes and inhibiting
several bacterial enzymes involved in the synthesis of DNA, RNA
and other metabolic enzymes.8
The current body of pharmacokinetic knowledge regarding
nitrofurantoin in both healthy subjects and patients with UTI is
suboptimal and based mainly on decades-old studies using
comparatively archaic laboratory and analytical techniques.9
Bioavailability is thought to be 80%.10 Except in patients with
severe renal failure, serum concentrations are almost undetect-
able, with peak levels of 1 mg/L.10,11 Indeed, nitrofurantoin
achieves therapeutically active concentrations only in the
lower urinary tract.12 For this reason it is recommended neither
for treatment of upper UTI nor for men with UTI and possible
concomitant prostatitis.
Nitrofurantoin was commercialized in an era predating require-
ments for robust methodology in drug development. Despite the
drug’s remarkable post-market resurgence and widespread
consumption, uncertainties persist regarding its true efficacy
and toxicity. For this reason we performed a structured, system-
atic review and meta-analysis of controlled clinical trials to evalu-
ate nitrofurantoin’s efficacy and toxicity when given short term
(≤14 days) for the treatment of UTI.
Methods
Using the MeSH descriptor ‘nitrofurantoin’, two reviewers (A. H. and E. V.)
searched the MEDLINE, EMBASE and Cochrane Library databases for all
published material from 1946 to December 2014. There were no language
restrictions. For the systematic review of nitrofurantoin’s efficacy and
toxicity when given for treatment of UTI, Preferred Reporting Items for
Systematic Reviews and Meta-Analyses guidelines were followed.13
Entry criteria for the systematic review on efficacy
and toxicity
For the systematic review of nitrofurantoin’s efficacy and toxicity when
given for UTI, only human controlled clinical studies, whether randomized
or not, were included. Studies evaluating nitrofurantoin as prophylaxis for
UTI were not included. Table 1 describes these entry criteria in detail.
Outcomes
This review’s primary outcome of interest is nitrofurantoin’s clinical
efficacy, as defined in the respective studies, for therapy of acute
UTI at short-term follow-up (≤6 weeks post-treatment completion).
Secondary outcomes, also assessed according to the definitions used in
the studies, are the incidence of nitrofurantoin-related adverse events
when given short term (≤14 days), short-term microbiological cure
after nitrofurantoin therapy, patient-reported outcomes (symptoms,
quality of life) and economic outcomes. All adverse events were evalu-
ated, but emphasis was placed on data specifically pertaining to gastro-
intestinal events (nausea, vomiting, abdominal pains, diarrhoea), skin
findings (including severe reactions such as Stevens–Johnson syndrome),
haematological and neurological events, pulmonary and hepatic fibrosis
and other reactions, and hospital admissions and death. When available,
results of ITT analyses were preferentially extracted over those of
per-protocol analyses.
Data extraction for the systematic review of efficacy
and toxicity
All article abstracts and/or main texts were reviewed independently by
A. H. and E. V. against the inclusion and exclusion criteria for the review’s
primary and secondary outcomes of nitrofurantoin efficacy and toxicity,
respectively. Both authors then independently conducted data abstraction
of the final sample, examining and recording the trial characteristics and
Figure 1. Trends in nitrofurantoin consumption in recent years. Nitrofurantoin’s DDDs per 1000 inhabitants per day are shown. The data from British
Columbia35 are representative of many regions and countries today.36,37 Consumption is increasing in some countries (Nordic countries except Finland,
Germany, Austria, Belgium, Poland), decreasing in France and still low in southern countries. Reproduced with permission from BC PharmaNet.
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outcomes using a pre-designed data abstraction form for information per-
taining to trial demographics, intervention, comparator(s), methodology,
outcomes and overall quality. Both reviewers’ results were then cross-
checked for reliability. Disagreements were resolved between the two
reviewers by discussion and consensus among all authors.
Risk of bias and quality assessment
A. H. and E. V. independently assessed the quality of studies using the
Cochrane Collaboration’s tool for assessing risk of bias.14 Inter-rater reli-
ability was assessed by means of inter-rater agreement percentages
and k values. While all studies meeting the inclusion criteria for efficacy
and toxicity evaluation were included in the review regardless of quality,
studies of stronger design and increased relevance to the primary aims
of the review were given more weight in the reporting of results.
Meta-analyses of randomized controlled trials
Meta-analyses were performed using Review Manager (version 5.3, Nordic
Cochrane Centre, Cochrane Collaboration, Copenhagen 2014). Risk ratios
(RRs) for dichotomous data (microbiological cure, clinical cure and adverse
effects) were calculated for individual trials with 95% CIs. Heterogeneity in
trial results was assessed using the I2 measure of inconsistency. When I2
was≤30% of the total analysis we used a fixed-effects model; otherwise a
random-effects model was used.14
Initially all randomized controlled trials were included, independent of
the antibiotic used as comparator and of respective dosing regimens; we
then excluded studies that: (i) did not disclose the exact number of
patients in the treatment arms; (ii) included men or children; (iii) compared
nitrofurantoin with placebo, drugs not used for UTI or a comparator admi-
nistered for ,3 days (excluding fosfomycin); and (iv) used an exclusively
microcrystalline nitrofurantoin formulation (currently out of use). Sensitivity
analyses were performed based on various selections of randomized con-
trolled trials in separate analyses.
Results
Figure 2 shows the results of the systematic search of the litera-
ture for trials on nitrofurantoin’s efficacy and toxicity when given
as treatment for UTI. Of 3586 articles on nitrofurantoin, 200 were
clinical trials. Of these, the majority were UTI prophylaxis studies,
pharmacokinetic/pharmacodynamic studies or investigations on
nitrofurantoin’s potential non-UTI uses. Ultimately, 27 studies,
24 of which were randomized, fulfilled entry criteria for the sys-
tematic review; these were subject to independent evaluation
for their content (Table S1, available as Supplementary data at
JAC Online) as well as their risk of bias and overall quality (below
and Table S2). Recent susceptibility studies were reviewed more
generally to provide the profile described below.
Risk-of-bias assessments and inter-rater agreement
Inter-rater agreement was strong, with 100% agreement (k 1.00)
in overall quality assessments and 89% – 100% agreement
(k 0.36–1.00) in risk-of-bias assessments (Table S2). While studies
predating 1990 fared significantly worse in both quality and
risk-of-bias assessments, neither reviewer considered any study
to be of high or excellent quality. Only a minority of studies
(12/27, 44%) were deemed to be of fair quality; the rest were con-
sidered to be of poor quality. All studies were judged to be at high
Table 1. Inclusion criteria for studies considered for the review of
nitrofurantoin’s efficacy and toxicity for therapy of lower UTI
Study design
Included:
† controlled clinical trials
Excluded:
† uncontrolled trials
Participants
Included:
† human patients of all ages and
both genders in all settings
Excluded:
† animal studies
† in vitro studies
Interventions
Included:
† oral nitrofurantoin at any dose
≤14 days for treatment of UTIa
Excluded:
† nitrofurantoin combined with
another antibacterial targeting
uropathogens
† nitrofurantoin for prostatitis
† nitrofurantoin for prophylactic
purposes
† nitrofurantoin for treatment of
conditions outside the
urinary tract
Comparators
Included:
† placebo
† no treatment
† a different drug
† nitrofurantoin at a different
dose, frequency or duration
Excluded:
† nitrofurantoin with another
antibacterial targeting
uropathogens
aIn literature published before 1990, asymptomatic bacteriuria was often
considered sufficient for a diagnosis of UTI.
3586 articles retrieved
Non-human studies
Non-clinical trials
Susceptibility studies,
pharmacokinetic/
pharmacodynamic studies,
non-UTI indications
UTI prophylaxis trials,
uncontrolled trials,
other exclusion criteria
2293 articles
200 articles
32 UTI treatment
57 UTI prophylaxis
24 randomized
3 non-randomized
89 studies
27 controlled studies
Figure 2. Flow chart for the retrieval of studies evaluated in the review of
nitrofurantoin’s efficacy and toxicity.
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risk for at least one major type of bias; most were at risk for several
types of bias. Thirteen (48%) were deemed at risk for all major
biases evaluated.
Clinical and microbiological efficacy of nitrofurantoin
for UTI
One of the first antibiotics available, nitrofurantoin was not subject
to controlled trials before or in the two decades following its
release. The first trials date from the 1970s, when nitrofurantoin,
by then considered the gold standard for UTI therapy, was used
as the comparator for several emerging antibiotics: trimethoprim/
sulfamethoxazole in the 1970s, then aminopenicillins, cephalos-
porins and fluoroquinolones in the 1980s (Table S1). Twenty-four
studies (89%) were randomized; 10 (37%) were either single or
double blind. The main patient population was adult women, but
six (22%) studies included both men and women, and three
(11%) included both adults and children. Many data were either
not presented or missing altogether; ITT analyses were rarely
done. In addition, before 1990, bacteriuria was often sufficient
for a diagnosis of UTI, whether symptomatic or not. Efficacy out-
comes were thus not always clinical, but rather microbiological in
patients who may not have been bothered by their bacteriuria.
The methodologically strongest studies date from the late
1990s and 2000s; these demonstrate overall equivalence between
nitrofurantoin when given for 5 or 7 days and trimethoprim/sulfa-
methoxazole,15 – 19 ciprofloxacin,16 – 19 amoxicillin20 and fosfomy-
cin,18,21 with clinical cure rates for the former varying between
79% and 92% in the different studies’ final follow-up.
Of note, nitrofurantoin appears to lose efficacy if given for only
3 days. In an open-label, randomized controlled trial, Hooton
et al.20 compared 3 day regimens of high-dose nitrofurantoin
(100 mg four-times daily), trimethoprim/sulfamethoxazole, cefa-
droxil and amoxicillin; 6 weeks post-therapy, nitrofurantoin’s clinical
efficacy was only 61%. Similarly, a 2002 trial by Christiaens et al.22
comparing 3 days of nitrofurantoin with placebo in young women
with symptoms of UTI and pyuria found clinical cure rates of 70%
versus 42%, respectively, 7 days after the start of therapy.
A meta-analysis for clinical cure and including all randomized
controlled trials (802 and 1345 patients receiving nitrofurantoin
and one of seven comparators, respectively) showed no significant
difference between nitrofurantoin and comparator (RR 0.99, 95%
CI 0.96–1.02), with moderate heterogeneity (I2¼35%). The nitro-
furantoin dosing regimens comprised five different schedules in
dose, frequency and duration (Figure 3). Indeed, the diversity in out-
comes was wide and the high risk of bias likely significant; a funnel
plot could not be drawn. Further analyses including only double-
blind randomized controlled trials or only studies deemed fair in
the quality assessment also showed no superiority of either treat-
ment (not shown).
Courses of 5 or 7 days of nitrofurantoin yielded microbiological
cure rates varying between slightly below 80% and 92%. Nine stud-
ies including 15 comparisons fulfilled criteria for the meta-analysis
assessing microbiological cure, with 616 patients receiving nitrofur-
antoin and 1046 patients receiving one of eight comparators
(Figure 4). Overall, the use of the comparator was more likely to
result in microbiological cure than nitrofurantoin (RR 0.93, 95% CI
0.89–0.97), with little heterogeneity (I2¼16%). When only double-
blind randomized controlled trials were included (results not
shown), the comparator still emerged with a more favourable
outcome, although the difference was not significant. A further
analysis including only studies deemed ‘fair’ in the risk-of-bias
and overall quality assessments yielded the same results, but
with no statistical significance.
The incidence of nitrofurantoin resistance among uropatho-
gens in patients failing therapy was not systematically assessed
as an outcome in the controlled studies. Gupta et al.18 evaluated
the emergence of antibiotic resistance among intestinal flora
after therapy with nitrofurantoin, ciprofloxacin or trimethoprim/
sulfamethoxazole. Four weeks after completing therapy, there
was no nitrofurantoin or trimethoprim/sulfamethoxazole resist-
ance in intestinal Escherichia coli isolates in women taking either
of these antibiotics, but of the 25 women taking ciprofloxacin, one
harboured two newly ciprofloxacin-resistant E. coli strains.18
Nitrofurantoin is not universally recommended for men with UTI
because of the possibility of concomitant infection of the prostate,
where the drug does not achieve therapeutic concentrations. While
six of the controlled trials included some male patients, baseline
demographics by study arm were rarely disclosed and results
were not stratified by gender; thus, no appraisal of nitrofurantoin’s
clinical or microbiological efficacy in men can be made.
Toxicity
In all studies reporting adverse event outcomes, toxicity was gen-
erally mild, reversible and predominantly gastrointestinal. No
study documented any severe or irreversible adverse outcome.
Microcrystalline versus macrocrystalline nitrofurantoin
Two of the earliest trials assessed compared nitrofurantoin mono-
hydrate with macrocrystalline nitrofurantoin for occurrence of
side effects.23,24 Both studies demonstrated a roughly 50% reduc-
tion in the occurrence of gastrointestinal side effects with the
macrocrystalline formulation, with comparable microbiological
efficacy. The clinical trials following these two studies used a
macrocrystalline formulation.
Toxicity of short-term nitrofurantoin
Seventeen of the 27 controlled trials measured the occurrence of
side effects due to nitrofurantoin as an outcome. In most of the
studies, nitrofurantoin was given for 5 or 7 days, but in 10 studies
conducted before 1983, it was given for either 10 or 14 days. The
prevalence of participants with side effects attributed to nitrofur-
antoin in the 17 studies generally ranged from 5% to 16%; nau-
sea, abdominal discomfort and headaches were described. An
exception was an open-label randomized controlled trial whose
primary outcome was quality of life.17 Side effects due to nitrofur-
antoin were reported by 49% of the women taking it, while 45%
and 62% of women taking trimethoprim/sulfamethoxazole and
ciprofloxacin, respectively, also reported side effects of a similar
intensity. Indeed, in all of the studies, the comparator drugs,
most often trimethoprim/sulfamethoxazole and ciprofloxacin,
fared similarly or worse, with reported side effect frequencies
often twice that of nitrofurantoin. A meta-analysis assessing
adverse effects (Figure 5) did not show a significant difference
between nitrofurantoin and any of seven comparators (RR 1.05,
95% CI 0.91–1.22), with no heterogeneity (I2¼0%).
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Other outcomes
Quality of life
In an open-label, randomized controlled trial comparing quality-
of-life outcomes for women taking either nitrofurantoin for 5 days
or trimethoprim/sulfamethoxazole or ciprofloxacin for 3 days,
there were no significant differences reported in quality of life in
any of the three treatment groups.17
Discussion
Nitrofurantoin’s clinical efficacy appears to be on par with that of
more contemporary antibiotics. The studies dating from the late
1990s and 2000s generally demonstrate the most robust method-
ology with more favourable risk-of-bias assessments, as well as
increased transparency regarding funding and potential conflicts
of interest. These studies indicate an overall equivalence between
nitrofurantoin when given for 5 or 7 days and trimethoprim/sulfa-
methoxazole, ciprofloxacin and amoxicillin, with clinical cure rates
for the former varying between 79% and 92% in the different
studies’ final follow-up. Meta-analyses for clinical cure confirmed
overall equivalence between nitrofurantoin and comparators.
Meta-analyses for microbiological cure, however, consistently
showed a slightly more favourable effect for comparators. The
practical significance of this finding is unclear, as almost none
of the studies addressed the emergence of post-treatment resist-
ance. In addition, the meta-analyses suffer from important
limitations such as the large variation and debatable quality of
the study designs. Comparisons were made against at least
seven antibiotics, with dosing regimens differing among them.
Independent quality assessments indicate that many of the ran-
domized controlled trials were likely biased; their use in the ana-
lyses is questionable and thus no firm conclusions can be drawn
from them.
Figure 3. Results of the meta-analysis for clinical efficacy. F, fair; P, poor (no studies were deemed to be of high or excellent quality); AMX, amoxicillin; CFR,
cefadroxil; CIP, ciprofloxacin; FOF, fosfomycin; NAL, nalidixic acid; OFX, ofloxacin; PMA, pipemidic acid; TMP, trimethoprim; SXT, trimethoprim/
sulfamethoxazole.
Systematic review
2460
In these studies, toxicity was minor, reversible and overall less
frequent than that of comparator drugs. Severe adverse drug
reactions were not observed. Indeed, the most feared side effects
of nitrofurantoin, pulmonary fibrosis and hepatotoxicity, have
been documented overwhelmingly in patients receiving nitro-
furantoin prophylaxis for several months or years.9 These
autoimmune-like phenomena are generally reversible when
a prompt diagnosis is made and nitrofurantoin immediately dis-
continued,25 but fatalities have been described.26 Other serious
side effects such as erythema multiforme, erythema nodosum,
agranulocytosis, megaloblastic anaemia and optic neuritis have
been described anecdotally,1 but were not reported in any of the
trials surveyed. Side effects, including the more common mild
gastrointestinal manifestations, appear to be an intrinsic property
of the nitrofurantoin molecule itself, in particular the 5-nitrofuran
moiety, although the switch from nitrofurantoin monohydrate to
predominantly macrocrystalline nitrofurantoin formulations in the
1960s led to improved tolerance. The accumulation of toxic
nitrofurantoin-derived metabolites was not observed in these trials,
as patients with renal insufficiency were excluded.
A strong publication bias likely contributes to the misperception
that nitrofurantoin hypersensitivity reactions are numerous.27 In
1985 at the height of its use, D’Arcy9 reviewed the major adverse
drug reactions to nitrofurantoin from published reports as well as
information submitted worldwide to the developers of the drug,
Norwich-Eaton Pharmaceuticals, by all manufacturers from all
sources. Calculated frequencies for all pulmonary reactions com-
bined and hepatic toxicity were 0.001% and 0.0003% of courses
of therapy, respectively. Other severe reactions were similarly
rare, with calculated frequencies for combined neurological and
haematological events at 0.0007% and 0.0004%, respectively.9
Antibacterial activity and resistance
Only 11 (41%) of the trials reported baseline resistance rates to
nitrofurantoin and comparators (Table S1), and only one
Figure 4. Results of the meta-analysis for microbiological cure. F, fair; P, poor; AMX, amoxicillin; CFR, cefadroxil; CIP, ciprofloxacin; FOF, fosfomycin; NAL,
nalidixic acid; OFX, ofloxacin; PMA, pipemidic acid; TMP, trimethoprim; SXT, trimethoprim/sulfamethoxazole.
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underpowered study18 assessed emergence of resistance as a for-
mal outcome. Baseline resistance was low (0%–5%) even in earlier
eras of widespread use. Likely because of nitrofurantoin’s multiple
modes of action, acquisition or emergence of resistance is relatively
infrequent. When it does occur, resistance is thought to be due to
loss of intracellular nitroreductase activity via sequential mutations
in the DNA regions encoding these enzymes.28,29 Indeed, despite
several decades of use, much of it prolonged and at lower doses
in the context of UTI prophylaxis, nitrofurantoin has generally
retained its broad-spectrum activity against Gram-negative and
Gram-positive bacteria, including most enterococci, but with the
important exception of some Klebsiella strains, Pseudomonas
aeruginosa and the Proteae (e.g. Proteus, Morganella and
Providencia spp.), which carry intrinsic resistance.8
In Western countries, resistance is still rare in E. coli and most
other ESBL-producing Enterobacteriaceae. A recent population-
based survey of in vitro antimicrobial resistance of urinary E. coli
isolates among US outpatients from 2000 to 2010 showed an
increase in nitrofurantoin resistance from 0.8% to 1.6%, while
increases in ciprofloxacin and trimethoprim/sulfamethoxazole
resistance were more marked, from 3% to 17.1% and from 17.9%
to 24.2%, respectively.30 The most recent susceptibility data from
E. coli community-acquired UTIs in Europe point to a similarly
low resistance prevalence (,2% from isolates in 2007–08).31
Nonetheless, nitrofurantoin resistance will likely increase with its
reintroduction as first-line therapy for uncomplicated UTI.4
Indeed, resistance rates among uropathogens in non-Western
countries are higher, with recent prevalence documented at
34.3%, 10.1% and 8.3% in India,32 Senegal33 and South Africa,34
respectively.
Conclusions
Once again recommended as first-line therapy for UTI, nitrofuran-
toin appears to have clinical efficacy equivalent to that of
trimethoprim/sulfamethoxazole, ciprofloxacin and amoxicillin,
although meta-analyses for microbiological cure indicate a
slightly more favourable effect for comparators. Nitrofurantoin
appears to achieve therapeutic concentrations only in the lower
urinary tract, restricting its indication to the treatment of lower
Figure 5. Results of the meta-analysis for adverse effects. F, fair; P, poor; AMX, amoxicillin; CFR, cefadroxil; CIP, ciprofloxacin; FOF, fosfomycin; NAL,
nalidixic acid; OFX, ofloxacin; PMA, pipemidic acid; TMP, trimethoprim; SXT, trimethoprim/sulfamethoxazole.
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UTI. Toxicity of short-term (≤14 days) nitrofurantoin is generally
mild and predominantly gastrointestinal. Hypersensitivity reac-
tions such as pulmonary fibrosis and hepatotoxicity were not
observed in persons taking short-term nitrofurantoin. Acquisition
of resistance to nitrofurantoin is still relatively rare, although is
likely to rise given recent increases in consumption. Of note, treat-
ment durations of at least 5 days appear to optimize efficacy.
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